RUA Life Sciences (RUA): ABISS product transfer MOU

This situation live

£14m · 23.0p · −10% since the first step

Disposal of a part (break-up)

ABISS product transfer MOU

Spun out, deconsolidated; testing planned 2027

DEC31 Next: animal studies on novel valve design in 415 days

Every step · 1

9 Nov 2026 Spun out, deconsolidated; testing planned 2027 – the Board is now delighted that ABISS and RUA have agreed a Memorandum of Understanding (“MOU”) with the customer, which will result in a transfer of the... ↗

What is happening

RUA Life Sciences: ABISS product transfer MOU – Spun out, deconsolidated; testing planned 2027. ['Spun out, deconsolidated; testing planned 2027']

In short: RUA Structural Heart was spun out during the year to 30 Sep 2026 with £3m of external convertible loan funding and £4.8m of intercompany balances capitalised. It is no longer consolidated, producing a non-recurring gain of about £4.8m. Testing planned during 2027 could be a value inflection point.
Announced: 9 Nov 2026 · MOU agreed with customer
External funding: £3 million convertible loan
Intercompany: £4.8 million of balances capitalised
Accounting gain: Non-recurring gain of approximately £4.8 million on loss of control
Cost to RUA pre spin-out: £0.2 million
Next milestone: Animal studies on novel AurTex leaflet valve design during 2027

animal studies on novel valve design (31 Dec 2027).

Briefing Pro

What it does, how it got here, what management promised and delivered – written from its own announcements.

From the company's own announcements. Not investment advice.

Also at RUA Life Sciences 0 open